⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
APVO News
Aptevo Therapeutics Inc
Form 8-K
sec.gov
APVO
Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant
accessnewswire.com
APVO
Form 8-K
sec.gov
APVO
Form 8-K
sec.gov
APVO
Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
accessnewswire.com
APVO
Form 8-K
sec.gov
APVO
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
accessnewswire.com
APVO
Form 8-K
sec.gov
APVO
Form 8-K
sec.gov
APVO
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
accessnewswire.com
APVO